Title

Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.

Document Type

Journal Article

Publication Date

11-16-2018

Journal

Drugs

DOI

10.1007/s40265-018-1009-0

Comments

Epub ahead of print

Peer Reviewed

1

This document is currently not available here.

Share

COinS